Ocular Therapeutix, Inc. $OCUL Shares Sold by Deutsche Bank AG

Key Points

• Deutsche Bank AG has reduced its stake in Ocular Therapeutix by 43.4%, selling 197,895 shares and now holding approximately 0.16% of the company, valued at about $1.89 million.
• Ocular Therapeutix reported a loss of ($0.39) earnings per share for the most recent quarter, missing analyst expectations, with revenues of $13.46 million, down 17.7% year-over-year.
• Despite ongoing losses, analysts maintain a consensus rating of "Buy" for Ocular Therapeutix, with a recent price target increase from Needham & Company from $14.00 to $15.00.

Deutsche Bank AG reduced its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 43.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 258,225 shares of the biopharmaceutical company's stock after selling 197,895 shares during the quarter. Deutsche Bank AG owned approximately 0.16% of Ocular Therapeutix worth $1,893,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OCUL. GF Fund Management CO. LTD. purchased a new position in Ocular Therapeutix in the fourth quarter valued at about $28,000. GAMMA Investing LLC grew its stake in Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 8,112 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 8,446 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Ocular Therapeutix in the first quarter valued at about $79,000. Finally, Walleye Capital LLC purchased a new position in Ocular Therapeutix in the fourth quarter valued at about $90,000. Hedge funds and other institutional investors own 59.21% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on OCUL shares. Scotiabank cut their target price on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, August 6th. Needham & Company LLC lifted their target price on Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Thursday, May 29th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $17.20.

Ocular Therapeutix Stock Performance

Shares of NASDAQ:OCUL traded down $0.43 during trading on Monday, hitting $11.87. The stock had a trading volume of 903,074 shares, compared to its average volume of 1,792,654. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $12.91. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -9.27 and a beta of 1.49. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The stock has a 50-day simple moving average of $10.91 and a two-hundred day simple moving average of $8.70.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The firm had revenue of $13.46 million during the quarter, compared to analysts' expectations of $13.12 million. During the same quarter in the previous year, the business earned ($0.26) earnings per share. The company's revenue for the quarter was down 17.7% compared to the same quarter last year. On average, equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.